Introduction
Bone fragility is a public health problem due to the accompanying increased morbidity, mortality, and financial costs resulting from fractures, in particular, non-vertebral and hip fractures. (1, 2) In women and men aged 50 years, the remaining lifetime risk for fragility fractures is 46% and 22%, respectively. (3) To reduce the burden of fragility fracture, a better understanding of the pathogenesis and mechanisms that influence on bone loss and result in fracture is needed.
Chronic inflammation is associated with a range of diseases such as rheumatoid arthritis and other autoimmune diseases, (4) cardiovascular diseases (5, 6) and diabetes mellitus. (7) There is an increasing body of evidence indicating that chronic diseases are associated with fragility fractures and that chronic inflammation is associated with fragility fractures even in the absence of disease. (8) (9) (10) Systemic diseases, such as rheumatoid arthritis, inflammatory bowel disease and systemic lupus erythematosus are associated with bone loss. (4, 8, 9) Each factor that contributes to bone loss expresses its effect through the final common pathway of bone modeling and remodeling, and bone loss is caused by the negative balance between bone formation and bone resorption within each of the bone multicellular units (BMU). (11) It has been established through in vitro experiments and rodent studies that inflammation plays a vital part in this remodeling process that is contributing to an increased bone resorption and in some cases inhibiting bone formation. (12) (13) (14) (15) In studies of low grade inflammation, higher levels of high-sensitivity C-reactive protein (CRP) are associated with an increased risk of fracture. (10, (16) (17) (18) (19) (20) (21) (22) (23) Some studies were relatively small, (10, 20) while one huge study of more than 18000 participants included only hospitalized fracture cases. (18) None of these previous studies have reported an effect of CRP on risk for fracture in women and in men in gender-stratified analyses. However, the association between levels of CRP and bone mineral density (BMD) is conflicting. (16, 21, 24, 25) A recent study showed that CRP was not associated with femoral neck and lumbar spine BMD, but inversely associated with bone strength index, which partially explained the increased fracture risk that was associated with inflammation. (17) We hypothesized that higher levels of CRP increase the risk of nonvertebral fracture in Tromsø, a population with a high incidence of fracture, and we aimed to test whether CRP is an independent risk factor for non-vertebral fractures, and whether CRP is associated with BMD, in both genders.
Materials and Methods

Participants
The Tromsø Study is a population-based, prospective study of various health issues and chronic diseases, and is a resource for the surveillance of disease risk factors. 
Variables
At baseline, two self-administered questionnaires were filled in, which included information on self-perceived health, chronic diseases, such as diabetes, cardiovascular diseases, asthma and cancer, and current use of medications, calcium and vitamin D supplementation, current smoking and level of physical activity. A physical activity score was made by adding the hours/week of moderate and hard leisure time physical activity, giving the hours with hard activity double weight: score = moderate + 2hard.
Participants were also asked to write a list of brand names of medicines used on a regular basis. The questionnaire information was checked by health personnel at the study site. The data collection is described in detail elsewhere. 
Baseline height and weight were measured in light clothing without shoes, and body mass index (BMI) was calculated as weight divided by the square of height (kg/m²).
BMD was measured at the total hip and femoral neck by Dual-energy X-ray Absorptiometry (DXA, GE Lunar Prodigy; Lunar Corporation, Madison, WI, USA).
(28)
The coefficients of variation (CV) were 1.2% and 1.7% for the total hip and femoral neck, respectively; details of the measurement methods, the strict quality control procedures for densitometry, and long-term performance of the densitometers are described previously.
CRP was measured by a particle-enhanced immunoturbidimetric assay from Roche Diagnostics, with a detection limit of 0.12 mg/l and the CV was 1.4%. Blood samples were analyzed at the Department of Clinical
Chemistry, University Hospital of North Norway, Tromsø. respectively. Women and men with higher levels of CRP had higher BMI, larger proportion of chronic diseases, and lower levels of physical activity, while men, not women with high CRP, were older, (all p for trend < 0,001, Table 1 women and 126 (8%) of 1648 men suffered at least one incident non-vertebral fracture. In women, each SD higher levels of log CRP increased the risk for non-vertebral fracture by 11% after adjustment for age and total hip BMD (HR 1.11; 95% CI 1.00-1.23, p = 0.053, Table 2 ). After further adjustment for height, BMI, previous fracture and self-reported chronic diseases the fracture risk increased by 13% (HR 1.13; 95% CI 1.02-1.26, p = 0.026). In men, each SD higher levels of log CRP increased the risk for non-vertebral fracture by 25% after adjustment for age and total hip BMD (HR 1.25; 95% CI 1.04-1.50, p = 0.018, Table 2 ). After further adjustment for height, BMI, previous fracture, selfreported and chronic diseases, the fracture risk increased by 22% (HR 1.22; 95% CI 1.00-1.48, p = 0.046). Those with CRP in the upper tertile exhibited 39% higher risk for fracture than those in the lowest tertile of CRP in women (HR 1.39, 95% Cl 1.06-1.83, p = 0.017), and 80% higher risk for fracture in men (HR 1.80 95% Cl 1.10-2.94, p = 0.019, Table 3) after accounting for BMD and other risk factors. Additional adjustment for use of medication, physical therapy and smoking made no substantial change in the result in both genders.
CRP and BMD In women, each SD higher levels of log CRP was associated with 0.16 SD and 0.12 SD higher BMD at the total hip and femoral neck after age adjustment and before (p < 0.001), but not after adjustment for BMI (p = 0.281 and p = 0.387, respectively, Table 4 ). In men, log CRP was not associated with BMD in age adjusted models (p = 0.609 and p = 0.259, respectively), however, after adjustment for BMI each SD higher levels of log CRP was associated with 0.08 SD and 0.09 SD lower BMD at the total hip and femoral neck (p = 0.001). Additional adjustment for comorbidity and other covariates made no substantial change in the result in both genders.
Discussion
We report that higher levels of CRP are associated with non-vertebral fractures after accounting for BMD in women and men in gender-stratified analyses. In men, not in hospitalized fractures were registered, as they did not screen the whole population. They reported U-shaped associations in both genders, albeit the associations were nonsignificant. (18) In our current study, there was a similar but non-significant U-shaped association.
Nakamura et al. reported an increased risk for vertebral and hip fracture in 751 elderly Japanese women above 69 years of age by higher levels of CRP. (16) Rolland et al. reported that men with the highest levels of CRP had higher odds for prevalent fracture than men with lower levels of CRP, but CRP levels were not associated with BMD at any site. (21) An interesting finding in that study was that higher CRP levels were associated with lower trabecular BMD, lower trabecular number and larger trabecular separation at the distal radius. However, the association between CRP and fracture remained unchanged after accounting for the trabecular microarchitecture.
Among 906 women and men between 40 and 79 years of age in the Bruneck study, higher levels of CRP were associated with a higher risk for fracture independent of BMD, bone turnover markers and chronic diseases. between CRP and fracture risk after adjusting for multiple variables. (19) They further reported the highest risk for fracture in subjects who had high levels of three or more inflammation markers in comparison with subjects with no elevated markers.
Eriksson et al. reported in a prospective study of 2910 elderly men that higher levels of CRP increased the risk for fracture, and these fractures were mainly vertebral, and the effect of CRP was independent of BMD and other risk factors. (23) In that study CRP was not significant associated with hip fracture or non-vertebral fragility fracture. Similarly, Oei et al. reported that CRP was most strongly associated with fracture of the spine, also significantly associated with hip fracture, but not with wrist fractures in a cohort of 6386 women and man with 1561 fractures in the Rotterdam Study. (22) CRP was not significantly associated with BMD in both studies. (22, 23) In cross-sectional and prospective studies, higher CRP is reported associated with a lower BMD and increased bone loss at both hip and spine. (24, 25) Other studies showed that BMD did not decrease by higher CRP levels. (16, 21) and two of them even reported a lower BMD with a lower CRP. (16, 17) In addition, prospective studies have reported no association between CRP and BMD in those women. (10, 19, 20, 22, 23) In the current study, higher CRP was associated with lower BMD in men not in women, in line with the previous conflicting results. An interesting finding was that after adjustment for BMI, a positive association between CRP and BMD changed to a non-significant negative association in women, which is similar as reported by ishii et al. (17) In contrast, this association changed from non-significant to a significant inverse association in men, in the current study. These changes were not explained by interaction between CRP and BMI and may need further investigation.
The uncertainties pertaining to associations between CRP and BMD suggest that CRP may modulate fractures risks through mechanisms other than by producing bone loss. One recent interesting study by Ishii et al. showed that compressive strength and bending strength indices at the femoral neck were inversely associated with CRP. (17) The calculation of these strength estimates were based on bone size and body size and proportions, known to be important for bone strength independent of BMD. (17) After accounting for these strength indices, the association between CRP and fracture risk was attenuated, and could partially explain the increased risk of fracture related to inflammation. (17) Another mechanism was suggested by Ding et al. who reported that a higher IL-6 was associated with a lower BMD after adjusted for other inflammatory markers such as TNF-a and CRP. 
while Rolland et al reported no association between BTM and CRP. (21) In addition, local rather than circulating inflammation markers may regulate bone remodeling via autocrine or paracrine mechanisms.
(25)
Our large population based study, which was based on a validated fracture registry, has several limitations. We did not include vertebral fractures in the registry. Cytokines and bone remodeling markers were not available, so we could not study whether the association between fracture risk and CRP was mediated via these factors as reported by others. (19, 35) Finally we did not have statistical power to study the association between CRP and different types of fracture.
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